Ascletis Pharma (HKG:1672) narrowed its attributable loss by 33% in the first half of 2025 to 88 million yuan from 130.3 million yuan in the year-ago period, a Friday Hong Kong bourse filing said.
Loss per share stood at 0.0914 yuan, down from 0.1282 yuan in the corresponding period of the last fiscal year.
The firm saw its total income for the six months rise 111% to 103.6 million yuan from 49 million yuan a year prior due to increased other income and gains.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.